Driver mutations' effect in secondary myelofibrosis: An international multicenter study based on 781 patients

Leukemia

Volumn 31, Issue 4, 2017, Pages 970-973

  Passamonti, F ^a   Mora, B ^a   Giorgino, T ^b   Guglielmelli, P ^c   Cazzola, M ^d   Maffioli, M ^a   Rambaldi, A ^d   Caramella, M ^e   Komrokji, R ^f   Gotlib, J ^g   Kiladjian, J J ^h   Cervantes, F ⁱ   Devos, T ^j   Palandri, F ^k   De Stefano, V ^l   Ruggeri, M ^m   Silver, R ⁿ   Benevolo, G ^o   Albano, F ^p   Caramazza, D ^a   Rumi, E ^d   Merli, M ^a   Pietra, D ^d   Casalone, R ^q   Barbui, T ^r   Pieri, L ^b   Vannucchi, A M ^c   more..

^a UNIVERSITY OF INSUBRIA   (Italy)

^b CNR   (Italy)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f OSPEDALE NIGUARDA CA GRANDA   (Italy)

^g H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^h STANFORD UNIVERSITY   (United States)

ⁱ SAINT LOUIS HOSPITAL   (France)

^j UNIVERSITY OF BARCELONA   (Spain)

^k UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^l UNIVERSITY OF BOLOGNA   (Italy)

^m CATHOLIC UNIVERSITY   (Italy)

ⁿ SAN BORTOLO HOSPITAL   (Italy)

^o WEILL CORNELL MEDICAL COLLEGE   (United States)

^p Centro Oncologico ed Ematologico Subalpino (COES)   (Italy)

^q UNIVERSITY OF BARI   (Italy)

^r OSPEDALE DI CIRCOLO   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; HEMOGLOBIN; JANUS KINASE 2; THROMBOPOIETIN RECEPTOR;

ADULT; AGED; CLINICAL FEATURE; FOLLOW UP; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LETTER; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUTATIONAL ANALYSIS; MYELOFIBROSIS; POLYCYTHEMIA; SPLEEN SIZE; SPLENOMEGALY; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOSIS; CLINICAL TRIAL; GENETICS; MIDDLE AGED; MUTATION; MYELOID METAPLASIA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; JANUS KINASE 2; MIDDLE AGED; MUTATION; PRIMARY MYELOFIBROSIS;

EID: 85007569806     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.351     Document Type: Letter

References (15)

1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al. The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391-2405
2. Passamonti F, Thiele J, Girodon F, Rumi E, Carobbio A, Gisslinger H et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood 2012; 120: 1197-1201
3. Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010; 24: 1574-1579
4. Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008; 22: 437-438
5. Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 2014; 28: 1472-1477
6. Rotunno G, Pacilli A, Artusi V, Rumi E, Maffioli M, Delaini F et al. Epidemiology and clinical relevance of mutations in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study on 359 patients of the AGIMM group. Am J Hematol 2016; 91: 681-686
7. Passamonti F, Rumi E, Caramella M, Elena C, Arcaini L, Boveri E et al. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood 2008; 111: 3383-3387
8. Hernandez-Boluda JC, Pereira A, Gomez M, Boque C, Ferrer-Marin F, Raya JM et al. The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and postpolycythemia vera myelofibrosis. Haematologica 2014; 99: e55-e57
9. Beauverd Y, Alimam S, McLornan DP, Radia DH, Harrison CN. Disease characteristics and outcomes in younger adults with primary and secondary myelofibrosis. Br J Haematol 2016; 175: 37-42
10. Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013; 27: 1861-1869
11. Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martinez-Trillos A, Casetti I et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood 2014; 124: 1062-1069
12. Pietra D, Rumi E, Ferretti VV, Buduo CA, Milanesi C, Cavalloni C et al. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia 2016; 30: 431-438
13. Elala YC, Lasho TL, Gangat N, Finke C, Barraco D, Haider M et al. Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia. Am J Hematol 2016; 91: 503-506
14. Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29: 392-397
15. Finazzi MC, Carobbio A, Cervantes F, Isola IM, Vannucchi AM, Guglielmelli P et al. CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis. Leukemia 2015; 29: 1209-1210